In this video, Motley Fool health-care analyst David Williamson discusses what investors should look for in Biogen Idec's upcoming earnings report, and what the Big Biotech has in store for 2013.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Foolish Preview: Biogen Earnings
By Dave Williamson
–
Jan 26, 2013 at 8:31AM
NASDAQ: BIIB
Biogen
Market Cap
$18B
Today's Change
(1.24%) $1.55
Current Price
$126.31
Price as of June 24, 2025, 4:00 p.m. ET
What investors should look for in Biogen's fourth quarter.
David Williamson has no position in any stocks mentioned. Follow him on Twitter: @MotleyDavid.
The Motley Fool recommends Quest Diagnostics. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
Biogen
BIIB
$126.31
(1.24%)
$1.55
Elan Corporation Limited
ELN
Teva Pharmaceutical Industries
TEVA
$17.12
(0.88%)
$0.15
Quest Diagnostics
DGX
$179.98
(0.14%)
$0.26
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
Biogen (BIIB) Q4 2024 Earnings Call Transcript
Biogen (BIIB) Q3 2024 Earnings Call Transcript
Biogen Exceeds EPS Estimate, Revenue Declines
Biogen (BIIB) Q2 2024 Earnings Call Transcript
Europe Just Turned Down Biogen's Alzheimer's Drug. Is the Stock One to Avoid, or a Bad News Buy?
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.